Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

LivaNova Launches RECOVER Trial Of VNS For Depression To Meet CMS CED Requirement

Executive Summary

LivaNova's RECOVER trial will randomize about 1,000 patients with treatment-resistant depression to either LivaNova’s vagus nerve stimulation therapy or a sham therapy and follow them for at least a year.

You may also be interested in...



LivaNova's Vagus Nerve Stimulator Earns CE Mark For Treating Depression

LivaNova announced its vagus nerve stimulator for depression earned the CE mark and said that marketing efforts will be limited in the EU and US.

MTI Outlook 2020: Medtechs Enter The Decade Of Digital, Consumers and Wellness

For health-care providers and medtech manufacturers alike, the decade ahead will require a coming to terms with digital technologies and integrating new methods of payment. Quality of service delivery remains the market-entry criterion, but companies will have to adapt to evolving health-care models. The stakes are high. Will manufacturers be able to capitalize on the changes in a market that is more competitive and unpredictable than ever?

Start-Up Spotlight: SetPoint Develops Vagus Nerve Stimulation To Treat Crohn's Disease And Rheumatoid Arthritis

SetPoint Medical is developing vagus nerve stimulation technology for Crohn’s disease and rheumatoid arthritis and believes it will be a "platform technology" for treating a variety of autoimmune diseases.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT124877

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel